Current development of the second generation of mTOR inhibitors as anticancer agents.
about
Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancerJudicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and PerspectivesHepatic signaling by the mechanistic target of rapamycin complex 2 (mTORC2)The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agentImbalanced mechanistic target of rapamycin C1 and C2 activity in the cerebellum of Angelman syndrome mice impairs motor function.Lithium Modulates Autophagy in Esophageal and Colorectal Cancer Cells and Enhances the Efficacy of Therapeutic Agents In Vitro and In Vivo.Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma.Mammalian target of rapamycin inhibitor RAD001 sensitizes endometrial cancer cells to paclitaxel-induced apoptosis via the induction of autophagy.Concurrent inhibition of mTORC1 and mTORC2 by WYE-687 inhibits renal cell carcinoma cell growth in vitro and in vivoCC-223 blocks mTORC1/C2 activation and inhibits human hepatocellular carcinoma cells in vitro and in vivo.Potential therapeutic approaches for Angelman syndrome.Glutamate, glutamate receptors, and downstream signaling pathwaysCombining molecular targeted drugs to inhibit both cancer cells and activated stromal cells in gastric cancer.Proteomic Profiling of Neuroblastoma Cells Adhesion on Hyaluronic Acid-Based Surface for Neural Tissue Engineering.Nanosecond Pulsed Electric Fields Enhance the Anti-tumour Effects of the mTOR Inhibitor Everolimus against Melanoma.The anti-cancer activity of the mTORC1/2 dual inhibitor XL388 in preclinical osteosarcoma models.Feedback loops blockade potentiates apoptosis induction and antitumor activity of a novel AKT inhibitor DC120 in human liver cancer.A proteomic view to characterize the effect of chitosan nanoparticle to hepatic cells: is chitosan nanoparticle an enhancer of PI3K/AKT1/mTOR pathway?Identification of mTOR as a primary resistance factor of the IAP antagonist AT406 in hepatocellular carcinoma cells.MHY1485 ameliorates UV-induced skin cell damages via activating mTOR-Nrf2 signaling.Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies.Preclinical study of CC223 as a potential anti-ovarian cancer agent.Activity of BKM120 and BEZ235 against Lymphoma Cells.Determination and validation of mTOR kinase-domain 3D structure by homology modeling.Pkb/Akt1 mediates Wnt/GSK3β/β-catenin signaling-induced apoptosis in human cord blood stem cells exposed to organophosphate pesticide monocrotophos.ERK inhibition sensitizes CZ415-induced anti-osteosarcoma activity in vitro and in vivo.Cell-Penetrating CaCO₃ Nanocrystals for Improved Transport of NVP-BEZ235 across Membrane Barrier in T-Cell Lymphoma.Therapeutic potential of a dual mTORC1/2 inhibitor for the prevention of posterior capsule opacification: An in vitro study.Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma.
P2860
Q27324821-D14ACF79-8584-4982-8C33-0DB691020615Q28071388-05ED565D-7A23-495D-9817-CBFCC3E18032Q28299373-3D94D3D2-6F03-4B90-8859-B2A837485E1EQ33728258-F791E566-08F5-405B-B17E-D82307193652Q35187482-BA522EA9-348F-4E04-B919-E24E5E14E0D6Q35738879-3131744B-4655-4A5B-98CF-77875DF768C1Q36211281-C4CC2252-3A2B-4B6E-843D-FC385F4F49F0Q36254815-03E69D6B-A717-4426-8A66-60FBC3804712Q36296641-73F54308-07A3-492C-B67F-8533FB8168E3Q36320156-E7271DA9-064A-4C91-9D0E-B7C420A92CA0Q36992786-8B841E34-AEF8-4776-96D7-13FD3D588C90Q37249255-7F7502C2-B196-4EEB-A1C7-FBA8963CC982Q37448103-968D2319-801B-45C0-8A7D-CD3A7E85E23BQ37521852-613F2B56-8AEA-4107-A723-6C52700CCB80Q37561380-9418EC3F-34E8-4F09-B695-0EBB57A391A2Q37580269-1D9F2202-7005-4EAE-96A1-C34E66250F14Q37680256-827CA67B-167E-452B-AD9F-71394A17D9BCQ37686640-B2E17687-403A-41F4-99D7-C7E3FE5ADB14Q37705988-500DAB22-35B3-4788-A71A-5A1648CD6097Q37706491-D4B10F1F-D2F9-4A90-B362-F66A94E811E4Q38793867-A2439619-902E-4949-9E41-028A0A39CA46Q41709197-609F318B-2CC0-4A14-835D-E2073762B9BDQ41855451-60C6CF9A-B02A-4300-96C4-13ADEF518B29Q42030014-5C76EFFE-0A4D-4AD9-A8E9-986A0594AF94Q42149242-16ED5008-2CFC-461E-8396-BDC68804749CQ47103348-81A5FD5E-1FC3-49FA-9A33-39AF8B661646Q48166570-0F68AC59-A8A2-4223-9E0F-5522AD5715B1Q49981867-19620738-CEDE-4CF0-A486-F4692AD546E6Q54110134-565CC2D8-5519-4BC0-BA7F-28E07DDC1025
P2860
Current development of the second generation of mTOR inhibitors as anticancer agents.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Current development of the second generation of mTOR inhibitors as anticancer agents.
@en
Current development of the second generation of mTOR inhibitors as anticancer agents.
@nl
type
label
Current development of the second generation of mTOR inhibitors as anticancer agents.
@en
Current development of the second generation of mTOR inhibitors as anticancer agents.
@nl
prefLabel
Current development of the second generation of mTOR inhibitors as anticancer agents.
@en
Current development of the second generation of mTOR inhibitors as anticancer agents.
@nl
P2860
P356
P1476
Current development of the second generation of mTOR inhibitors as anticancer agents.
@en
P2093
Hong-Yu Zhou
P2860
P356
10.5732/CJC.011.10281
P50
P5008
P577
2011-11-04T00:00:00Z
2012-01-01T00:00:00Z